vTv Therapeutics (NASDAQ:VTVT – Get Free Report) posted its quarterly earnings data on Wednesday. The biotechnology company reported $1.65 earnings per share for the quarter, beating the consensus estimate of $0.21 by $1.44, Zacks reports. The business had revenue of $36.84 million during the quarter, compared to the consensus estimate of $20.00 million.
vTv Therapeutics Price Performance
Shares of NASDAQ:VTVT traded up $3.75 during trading on Thursday, reaching $35.42. The stock had a trading volume of 29,064 shares, compared to its average volume of 44,631. vTv Therapeutics has a 52 week low of $14.00 and a 52 week high of $44.00. The business’s 50-day moving average price is $35.88 and its 200 day moving average price is $33.94. The stock has a market capitalization of $139.50 million, a PE ratio of -10.72 and a beta of 0.26.
Analysts Set New Price Targets
Several research analysts recently issued reports on VTVT shares. Wall Street Zen raised shares of vTv Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, March 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of vTv Therapeutics in a research note on Friday, March 27th. BTIG Research reissued a “buy” rating and issued a $49.00 target price on shares of vTv Therapeutics in a report on Wednesday, March 11th. Evercore assumed coverage on vTv Therapeutics in a research report on Thursday, March 12th. They set an “outperform” rating and a $44.00 target price for the company. Finally, Roth Mkm initiated coverage on vTv Therapeutics in a research report on Thursday, January 22nd. They issued a “buy” rating and a $58.00 price target on the stock. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $53.00.
Institutional Inflows and Outflows
A number of institutional investors have recently modified their holdings of the company. Geode Capital Management LLC raised its stake in shares of vTv Therapeutics by 84.3% in the fourth quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock valued at $1,128,000 after acquiring an additional 12,896 shares during the last quarter. 683 Capital Management LLC bought a new position in shares of vTv Therapeutics in the fourth quarter valued at approximately $731,000. Finally, Goldman Sachs Group Inc. bought a new position in shares of vTv Therapeutics in the fourth quarter valued at approximately $221,000. Institutional investors own 17.51% of the company’s stock.
About vTv Therapeutics
vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.
The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.
Read More
- Five stocks we like better than vTv Therapeutics
- The Great SPR Arbitrage: An Oil Market Glitch Fuels Sector Gains
- Why Satellogic Could Be One of the Biggest Space Winners of 2026
- Dividend Growth or High Yield: The Income Investor’s Bet
- A New Focus for GoPro: Is a Takeover in the Frame?
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
-limited-logo-1200x675.png){kind=logo}
